UPM, a division of Gregory Pharmaceutical Holdings, Inc., has reached an agreement with Amerigen...
Approximately 25% of drugs in development worldwide are classified as highly potent, with this...
No two packaging projects are alike and in order to make it all work and to keep everything on...
Catalent Pharma Solutions today announced that based on compelling data generated by the SMARTag™ ADC platform, it has increased its minority investment in Redwood Bioscience.
AMRI has signed a definitive agreement to acquire all the outstanding shares of Cedarburg Pharmaceuticals, Inc. for $38.2 million in cash. The transaction, including $2.8 million of assumed liabilities, is valued at $41 million.
Charles River Laboratories International, has entered into a definitive agreement to acquire the CRO services division of Galapagos NV, which includes both Argenta and BioFocus.
The March issue of Pharmaceutical Processing is our INTERPHEX 2014 show issue and features numerous highlights from show exhibitors. In addition, we also announce the winners in our new Facility Excellence Awards program.
With the merger, the company extends its global footprint to include 20 operational offices in 15 countries, including new offices in Taiwan, China, Hong Kong, South Korea, Vietnam, Singapore, and Malaysia.
In a new agreement, PBI will provide access to its extensive menu of validated biomarker assays to support WuXi's integrated clinical trial testing services. This includes bioanalysis and central laboratory services for pharmaceutical and biotech companies performing clinical drug development in China.
Almac has announced the expansion of its clinical services and technologies capabilities to include on-the-ground leadership as well as technical, project and operational resources in Asia. The company has established regional hubs in Singapore and Japan to better enable the industry’s growing need to conduct clinical trials in Asia and/or manage global trials from the region.
Progenitor Cell Therapy has expanded both its Allendale, NJ and Mountain View, CA current Good Manufacturing Practice facilities to significantly increase its engineering and process development laboratories, and controlled environment space available for client needs.
The movement toward transparency is global, touching almost every aspect of society. Whether the topic is NSA eavesdropping in the U.S. or banking practices in the European Union, transparency and accountability go hand in hand. The pharma industry is no different.
The Norwich Pharma Services manufacturing facility in Norwich, New York is as varied in its capabilities as it is its equipment investment strategy. This dedication to growth through equipment and technology investment has led to it being recognized as one of Pharmaceutical Processing’s Facility Excellence Award winners for 2014.
Custom Processing Services has a strong track record of contract manufacturing in the pharmaceuticals marketplace. And on November 11, 2011 that legacy was strengthened with the opening of a 42,000 square foot facility dedicated to GMP processing, with two unique GMP processing stations. This commitment has led to it being recognized as one of Pharmaceutical Processing’s Facility Excellence Award winners for 2014.
New development technologies, expanded contract manufacturing and service capabilities, as well as innovative equipment investment strategies highlight leading practices from the best in pharmaceutical processing comprise the 2014 Pharmaceutical Processing Facility Excellence Award winners.
Olympus Biotech today announced the initiation of an aggressive transaction process to find a buyer of its West Lebanon, NH manufacturing facility over the next 90 days. In recent months, the Company has received interest from buyers and contract manufacturing organization (CMO) partners, but no deal has been consummated yet.
The Jan/Feb 2014 issue of Pharmaceutical Processing is our INTERPHEX 2014 Preview issue and features numerous exhibitor highlights and a guide to the educational conference program. In addition, we profile Xcelience, a clinical trial material contract manufacturer based in Tampa, FL.
Pharmaceutical Processing's Editor In Chief Mike Auerbach discusses current and future outsourcing trends with a select group of companies.
Mayne Pharma Group Limited has named Stefan Cross as president of Mayne Pharma USA. Cross is responsible for leading all of Mayne Pharma’s existing business operations in the United States, and for spearheading new business development initiatives.
Metrics Inc. is a full-service global CDMO. Our expertise includes FTIM formulations, Phases I-III CTM manufacturing and analytical support services leading to commercial manufacturing.
LSNE is a CMO with a proven regulatory history, specializing in process development, aseptic fill/finish and lyophilization. No matter what stage of development you are in, our development team can partner with you to optimize your manufacturing process.
OSO BioPharmaceuticals Manufacturing LLC is a CMO that delivers injectable sterile liquid, suspension and lyophilized biologic and pharmaceutical products to the pharmaceutical industry.
Unique Pharmaceuticals, Ltd. has voluntarily registered with the U.S. Food and Drug Administration (FDA) as a Human Drug Compounding Outsourcing Facility following guidance from the recently enacted Drug Quality and Security Act.
SP Scientific and AAIPharma Services Corp. have entered into a purchase agreement where SP will supply AAIPharma with a LyoStar 3 pilot-scale lyophilizer paired with a complementing Hull production-scale lyophilizer, both equipped with Praxair’s ControLyo™ Nucleation On-Demand Technology.
CCBR-SYNARC and BioClinica, Inc. have signed an agreement to merge their companies to create a global provider of specialized outsourced clinical services. The combined company will offer a portfolio of services uniquely tailored to conducting and managing global clinical trials on behalf of the world's premier pharmaceutical and biotechnology companies.
A focus on core competencies allows Xcelience to deliver clinical trial materials with speed, efficiency and quality.
AAIPharma Services a provider of pharmaceutical analytical testing, product development and manufacturing services, announced today that it has completed a multi-million dollar expansion of its cGMP parenteral manufacturing facility in Charleston, S.C.
Outsourcing of biopharmaceutical manufacturing has been growing for several years, to the point where contract manufacturing has become a common strategic decision for developers, extending beyond simple non-core activities and into more high-value, technical ones that leverage offerings from contract manufacturing organizations (CMOs) that some developers do not have in-house.
- Page 1